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Abstract
Background: BCG vaccination is administered in infancy in most countries with the aim of providing protection against
tuberculosis. There is increasing interest in the role of vitamin D in immunity to tuberculosis. This study objective was to
determine if there was an association between circulating 25(OH)D concentrations and BCG vaccination status and cytokine
responses following BCG vaccination in infants.
Methods: Blood samples were collected from UK infants who were vaccinated with BCG at 3 (n=47) and 12 (n=37) months
post BCG vaccination. These two time-points are denoted as time-point 1 and time-point 2. Two blood samples were also
collected from age-matched unvaccinated infants (n=32 and 28 respectively), as a control group. Plasma vitamin D
concentrations (25(OH)D) were measured by radio-immunoassay. The cytokine IFNc was measured in supernatants from
diluted whole blood stimulated with M.tuberculosis (M.tb) PPD for 6 days.
Results: 58% of infants had some level of hypovitaminosis (25(OH)D ,30ng/ml) at time-point 1, and this increased to 97% 9
months later. BCG vaccinated infants were almost 6 times (CI: 1.8–18.6) more likely to have sufficient vitamin D
concentrations than unvaccinated infants at time-point 1, and the association remained strong after controlling for season
of blood collection, ethnic group and sex. Among vaccinees, there was also a strong inverse association between IFNc
response to M.tb PPD and vitamin D concentration, with infants with higher vitamin D concentrations having lower IFNc
responses.
Conclusions: Vitamin D may play an immuno-regulatory role following BCG vaccination. The increased vitamin D
concentrations in BCG vaccinated infants could have important implications: vitamin D may play a role in immunity induced
by BCG vaccination and may contribute to non-specific effects observed following BCG vaccination.
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Introduction
BCG vaccination is administered in infancy in most countries
with the aim of providing protection against mycobacterial
infections such as tuberculosis and leprosy [1]. There has been
debate about possible non-specific effects of BCG vaccination.
Observational studies from low-income countries (Guinea-Bissau,
Bangladesh, Papua New Guinea and Malawi) have indicated that
BCG may have a beneficial effect on all-cause childhood mortality
[2,3,4,5], but there has been concern about possible confounding
in these studies [6]. In one study, BCG was shown to influence
responses to other vaccinations in infancy, with infants who receive
BCG at birth along with their first Hepatitis B vaccine (HBV),
having higher antibody, in vitro T cell proliferative and IFNc
responses to hepatitis B surface antigen two weeks after their HBV
booster, than infants whose BCG vaccination was delayed [7]. As
well as the evidence that BCG provides protection against
mycobacterial infections such as tuberculosis and leprosy [8],
studies have suggested that BCG vaccination may offer protection
or beneficial effects in inflammatory and autoimmune conditions
such as asthma, allergic diseases, Crohn’s disease, diabetes, some
cancers including bladder cancer [9] and helminth infections [10].
Vitamin D deficiency is now recognised as widespread [11] and
is more common in TB patients than controls [12,13,14]. Patients
with tuberculosis have, on average, lower serum concentrations of
25(OH)D than healthy controls [15]. A recent placebo controlled
trial giving Vitamin D supplements along with TB chemotherapy
failed to show evidence for an overall effect on clinical outcome or
mortality, although this may have been due to the dose or dosing
schedule [16].
In the last five years there has been renewed interest in the
biological effects of Vitamin D on tuberculosis due to the growing
evidence of the immunomodulatory properties of Vitamin D.
Vitamin D alone has no direct anti-mycobacterial action, but its
active metabolite 1a25(OH)2D modulates the host response to
M.tb infection [17]. Toll Like Receptor (TLR) mediated activation
of macrophages up-regulates expression of the Vitamin D
receptor, leading to the induction of the antimicrobial peptide
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of adequate serum 25(OH)D (in African-American patients in the
US) led to reduced induction of cathelicidin mRNA and
impairment in mycobacterial growth inhibition [18]. Further
studies confirmed that Vitamin D induced M.tb growth restriction
is dependent on the induction of cathelicidin [19].
Vitamin D has also been shown to have an immuno-regulatory
role in vitro. It has been shown to inhibit differentiation and
maturation of dendritic cells and to act on T lymphocytes to
inhibit T cell activation and proliferation resulting in altered
cytokine expression [20]. It has recently been shown to be
important in controlling T cell receptor signalling [21]. In vitro
studies have shown that Vitamin D inhibits the generation of Th1
responses [22] and the production of IFNc by previously activated
T cells. It has been suggested that Vitamin D may promote the
generation of regulatory T cells (Treg) [23]. Thus paradoxical
effects of vitamin D have been observed in immunity of
tuberculosis: vitamin D decreased Th1 mediated immunity, but
increased bactericidal activity [24].
In this study, we measured 25(OH)D, which is considered to be
the most reliable indicator of Vitamin D status [25], in plasma
samples from UK infants who had received BCG vaccination and
in age-matched infants who had not been vaccinated. We aimed to
determine if there was an association between circulating
25(OH)D concentrations and BCG vaccination status and
cytokine responses following BCG vaccination in UK infants.
Materials and Methods
Recruitment and study design
BCG vaccinated and unvaccinated infants were recruited in
Redbridge and Waltham Forest Primary Care Trusts respectively
after written informed consent from parents or guardians. These
two similar, neighbouring Primary Care Trusts in North London
had different BCG vaccination policies in place during the study
period between March 2003 and November 2005; infants in
Redbridge PCT were routinely offered BCG while those in
Waltham Forest were not offered BCG. Two blood samples were
taken, at time-points which we subsequently denote as time-point
1 and time-point 2. Blood samples were taken 3 months (infants
aged approximately 6 months: n=47 vaccinated, n=32 unvac-
cinated) and 12 months (infants aged approximately 15 months:
n=37 vaccinated, n=28 unvaccinated) post-vaccination in
vaccinees, and controls were age-matched to the infants who
received BCG vaccination. Diluted whole blood assays, IFNc
ELISAs and vitamin D assays were performed on blood samples at
both time-points. Approval for the study was given by the
Redbridge and Waltham Forest Health Authority Local Research
Ethics Committee, and the Ethics Committee of the London
School of Hygiene & Tropical Medicine.
Vitamin D assay
Total plasma 25-hydroxyVitamin D (25(OH)D) was measured
by Radio-immuno assay (RIA) with
125 I labelled 25(OH)D as a
tracer, using a kit from Diasorin (Diasorin S.p.A., Saluggia, Italy)
following the manufacturer’s instructions. Briefly, 25(OH)D was
extracted from plasma samples with acetonitrile. After centrifuga-
tion, an aliquot of the supernatant was incubated for 90 minutes
with
125 I labelled 25(OH)D and 25(OH)D antibody. A second
antibody precipitating complex was then added and incubated for
20 minutes, followed by the addition of a non-specific binding
buffer for 20 minutes to reduce non-specific binding. After
centrifugation, the supernatant was decanted and the radioactivity
was measured on a c-counter for two minutes or until 10,000
counts, whichever came first.
Hypovitaminosis was defined as plasma 25(OH)D ,30 ng/ml
(75 nmol/l), graded as severe Vitamin D deficiency (sVDD) for
plasma 25(OH)D ,10 ng/ml (25 nmol/l), mild Vitamin D
deficiency (mVDD) for plasma 25(OH)D 10–19.9 ng/ml (25–
50 nmol/l), and Vitamin D insufficiency (VDI) for plasma 25
(OH)D 20–29.9 ng/ml (50–75 nmol/ml) [12,13].
The quality and reproducibility of the assay was determined
using the quality controls provided with the kit. Two controls were
provided and the coefficient of variation for all kits used was 17%
for the low control and 18% for the high control. The controls fell
within the acceptable range given by the manufacturer.
Whole blood assay, IFNc ELISA
Whole blood assays and ELISAs for IFNc were carried out as
described elsewhere [26,27]. Heparinised whole blood was diluted
1 in 10 and cultured on the day of collection with the M.tb PPD
(Statens Serum Institut, Copenhagen (SSI), RT49, lot 204) at a
concentration of 5 mg/ml or medium alone (unstimulated) as the
negative control. Cultures were incubated at 37uC with 5% CO2;
supernatants were harvested on day 6 and stored at 270uC until
assayed for IFNc in single 100 ml samples by quantitative ELISA.
Reproducibility was determined by duplicate positive control
samples run on each ELISA plate, during the time-period of the
study two different controls were used and the coefficient of
variation between plates was 7% and 19% for the two controls.
Statistical analysis
Data were analysed using Stata 10. Chi squared tests were used
to assess 1) differences in Vitamin D concentrations between BCG
vaccinated and unvaccinated infants; 2) differences in the
proportion of IFNc responders in BCG vaccinated and unvacci-
nated UK infants; and 3) differences in the proportion of IFNc
responders according to their Vitamin D response, among
vaccinees. Linear regression was used to compare mean
differences in Vitamin D concentrations, and logistic regression
to calculate odds ratios for Vitamin D sufficiency, according to
BCG vaccination status, season of blood collection, ethnic group
and sex. Ethnic group was divided into ‘‘Caucasian’’ (which
included infants whose mothers described them on the consent
form as ‘‘White British, White Irish or White other’’) and ‘‘Non-
Caucasian’’ (which included ‘‘Asian Pakistani, Black African,
Black Caribbean, Mixed White and Black Caribbean, Mixed
White and Black African, Mixed White and Asian’’). Stratified
analyses of the effect of BCG vaccination on the vitamin D
response, by season of blood collection, ethnic group and sex, were
conducted to investigate confounding and effect modification.
Finally, multivariable linear and logistic regression analysis was
conducted to calculate mean differences and odds ratios for the
effect of BCG vaccination on the vitamin D concentration,
controlled for other infant characteristics. Multivariable linear
regression was used to estimate the effect of vitamin D
concentration on the IFNc response, controlled for season of
birth and season of blood collection.
Results
Vitamin D sufficiency
Vitamin D (25(OH)D) was measured in plasma samples from
infants 3 months post BCG (n=47) and in unvaccinated controls
(n=32) (n=79 total) and in samples from infants 12 months post
BCG (n=37) and in age-matched unvaccinated controls (n=28)
(n=65 total). The median concentration of Vitamin D in all the
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decreased significantly by time-point 2 when the median was
18.9 ng/ml (P,0.0001) (Figure 1).
At time-point 1, only 42% (33/79) of infants were considered to
have Vitamin D sufficiency (VDS) (.30 ng/ml), while the
remaining infants had some level of hypovitaminosis (,30
ng/ml): 8% (6/79) had severe Vitamin D deficiency (sVDD) (0–
9.9 ng/ml), 17% (13/79) had mild Vitamin D deficiency (mVDD)
(10–19.9 ng/ml) and 34% (27/79) had Vitamin D insufficiency
(VDI) (20–29.9 ng/ml). Nine months later, at time-point 2, only
3% (2/65) of all infants had Vitamin D sufficiency, while the
remaining infants showed evidence of hypovitaminosis: 9% (6/65)
sVDD, 51% (33/65) mVDD and 37% (24/65) VDI (Tables 1
and 2).
Factors associated with Vitamin D sufficiency
There was no evidence that Vitamin D concentration was
affected by ethnicity or sex at time-point 1, while there was strong
evidence that BCG vaccination status had an effect on Vitamin D
levels. BCG vaccinated infants’ mean Vitamin D concentrations
were 6.3 ng/ml higher than unvaccinated infants (P=0.01) and
the odds of a vaccinated infant having sufficient Vitamin D were
5.85 times higher than an unvaccinated infant (C.I 1.84, 18.57,
P=0.0007) (Figure 1, Table 1). There was also evidence that
Figure 1. Histograms of 25(OH)D at time-point 1 and 2. 25(OH)D was measured in plasma samples from infants 3 and 12 months post BCG
vaccination, and in age-matched unvaccinated controls. 25(OH)D in BCG vaccinated and unvaccinated infants a] in vaccinated infants and
unvaccinated controls combined at time-point 1 and b] in vaccinated infants and unvaccinated controls combined at time-point 2; 25(OH)D in infants
grouped according to BCG vaccination status at c] time-point 1 and d] time-point 2.
doi:10.1371/journal.pone.0016709.g001
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concentration of Vitamin D, with blood samples which were
taken in spring and winter having lower Vitamin D than those
taken in summer and autumn (P=0.011).
By time-point 2, Vitamin D levels had decreased significantly
(P,0.0001), and only 3% (2/65) of infants had ‘‘sufficient’’
Vitamin D according to the defined cut-offs used. In order to
assess associations with Vitamin D status infants were divided into
those who had less than 20 ng/ml (with severe or mild deficiency)
and those with greater than 20 ng/ml (with insufficiency or
sufficiency). Again, there was evidence that Vitamin D concen-
trations were higher among those who were BCG vaccinated
compared to those who had not received BCG vaccination,
although this association was weaker than at 3 months post BCG.
BCG vaccinated infants had a mean Vitamin D concentration that
was 3.5 ng/ml higher than unvaccinated infants and BCG
vaccinated infants had 3.2 times the odds of having Vitamin D
levels above 20 ng/ml than unvaccinated infants (P=0.033)
(Table 2). There was also strong evidence of an association with
season of blood sample collection, with blood samples taken in the
summer and autumn having higher Vitamin D levels (P=0.0051).
There was no evidence of an association between vitamin D
concentration and either ethnic group or sex, although there was a
trend of higher Vitamin D concentrations in Caucasian infants
compared to non-Caucasians and in females compared to males
(P=0.13, P=0.17 respectively) (Table 2).
Vitamin D levels remained associated with BCG vaccination
status at time-point 1, both after controlling one at a time for
season of blood collection (P=0.004), ethnic group (P=0.0005),
and sex (P=0.0008), and after controlling simultaneously for these
factors (P=0.006), although the association was weakened (mean
difference 6.3 unadjusted, 3.3 after controlling for all of season of
blood collection, sex, and ethnic group) (Table 3). Restricting to
Caucasian infants to remove any residual confounding by ethnicity
(n=59) confirmed the association remained strong; the BCG
vaccinated group were 7.2 times more likely to be vitamin D
sufficient, than the unvaccinated group. By time-point 2, Vitamin
D levels remained associated with BCG vaccination status, and
controlling for season of blood collection, ethnic group and sex
strengthened the association slightly (mean difference 3.5 unad-
justed, 4.4 in adjusted analysis) (Table 4).
Association of Vitamin D and IFNc responses to M.tb PPD
At 3 months post BCG vaccination, there was strong evidence
of an inverse association among vaccinees between IFNc response
to M.tb PPD and Vitamin D concentrations, with a moderately
strong negative correlation (r=20.4, P=0.004) (Figure 2,
Table 3). BCG vaccinated infants with higher levels of Vitamin
D( .30 ng/ml) had lower mean IFNc responses to M.tb PPD than
infants with lower Vitamin D levels 3 months post BCG
(P=0.030). There was also a trend of an inverse association at
12 months, though this did not reach statistical significance and
the confidence interval was wide (P=0.255) (Table 5). After
controlling for season of blood collection, the mean difference in
IFNc responses in infants with low and high Vitamin D increased
slightly (Table 5).
Discussion
Vitamin D Sufficiency
A high percentage (58% at age 6 months and 97% at age 15
months) of Vitamin D hypovitaminosis (25(OH)D ,30 ng/ml)
was found in this study of UK infants. Globally, it has been
recognised that there is widespread Vitamin D deficiency [28],
however there are no recently published data on the prevalence of
Vitamin D deficiency in UK children aged ,18 months. A study
examining Vitamin D levels in children in London with active or
latent tuberculosis recently showed that 86% (55/64) of children
(aged 0.1 to 17 years) had hypovitaminosis, most of whom were
South Asian or Black African [29]. Much of the focus of research
in the UK has been on Vitamin D deficiency in Asian children
[30] however, Vitamin D insufficiency has been shown to be
common in pregnant Caucasian women from Southampton [31],
resulting in predictions that Vitamin D insufficiency is also
common in Caucasian infants in the UK, given that a woman’s
Vitamin D serum concentration during pregnancy is strongly
predictive of her child’s concentration at birth [25]. The results
from our study provided no evidence of an effect of ethnicity on
vitamin D concentrations in UK infants, as similar levels of
hypovitaminosis were seen in Caucasian and non-Caucasian
infants.
Our results provide evidence for a decrease in Vitamin D levels
in UK infants between age 6 and 15 months. One explanation for
the observed decrease in Vitamin D levels could be due to higher
levels shortly after birth due to uptake via the placenta, followed by
a decrease over time if infants were continuously breast fed
(without supplementation, breast milk has been shown to contain
low levels of Vitamin D [25]).
Plasma vitamin D is associated with BCG vaccination
status
Many factors have been found to influence circulating Vitamin
D levels such as sunlight exposure, skin pigmentation, use of
sunscreen, latitude, season, clothing, diet and supplementation
[25]. Our results are the first to show that BCG vaccination
influences Vitamin D concentrations. At time-point 1, the odds of
having sufficient Vitamin D levels were approximately six times
higher in vaccinated than unvaccinated infants, and this effect
remained strong after controlling for seasonal effects. There have
been studies which have shown effects of BCG on asthma, allergic
diseases, cancers, and immune responses to other childhood
vaccinations [7,9]. These effects of BCG vaccination could be
partly due to the vaccine’s effect in activating antigen presenting
cells such as dendritic cells and macrophages, with resulting potent
Th1 activation. Such effects may be particularly important in
infants, since they have immature dendritic cells at birth that may
be matured following BCG vaccination [32]. There is increasing,
although inconsistent, evidence that BCG vaccination plays a role
in the maturation of the immune system and in the development
and balance of regulatory pathways [9]. Vitamin D has also been
shown to play a role in immuno-regulation, and is thought to be
involved in many autoimmune and inflammatory diseases such as
multiple sclerosis, type-1 diabetes, rheumatoid arthritis and
systemic lupus erythematosis; cardiovascular diseases and cancers
[20]. Given the finding that BCG vaccinated infants had higher
concentrations of plasma Vitamin D than unvaccinated infants, it
is possible that part of the non-specific effects that have been
attributed to BCG vaccination may be due to increased Vitamin D
levels. It is still unclear what the ideal magnitude of circulating
25(OH)D is, and thus it is not known whether the difference in
magnitude of 25(OH)D between vaccinated and unvaccinated
infants seen in this study is clinically significant.
Proposed mechanism of BCG vaccination resulting in
increased vitamin D
BCG vaccination is given intradermally, where it is first
phagocytosed by macrophages and antigens are then presented
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16709and processed by macrophages and dendritic cells. It is probable
that this is followed by trafficking to the lymph nodes in mobilised
dendritic cells, and that T cell responses are then stimulated in the
lymph nodes. In the last 5 years, there has been much evidence
that vitamin D synthesis occurs not just by the classical pathway in
the liver and kidneys, but that it can also occur within
macrophages and dendritic cells as they possess all the necessary
enzymes for its synthesis [18,20,33,34,35]. M.tb antigens activate
TLR1 and TLR2 on macrophages resulting in increased
production of 1a-hydroxylase and increased expression of VDR
resulting in the production of cathelicidin, which has antimyco-
bacterial properties [18]. We propose that mycobacterial antigens
in BCG may also increase production of the 25 hydroxylase
enzymes, resulting in increased production of 25(OH)D.
The scar generated following BCG vaccination matures and
heals over several months, suggesting that immunological
processes occur at the site of inoculation for some time. The
increased vitamin D concentrations observed in this study could be
due to increased local production in macrophages and dendritic
cells following BCG vaccination. It is, however, surprising that this
Figure 2. Association of IFNc to M.tb PPD with 25(OH)D concentrations 3 months post BCG vaccination. 25 (OH) D was measured in
plasma samples and IFNc to M.tb PPD was measured by ELISA from supernatants from 6 day cultures of diluted whole blood from infants 3 months
post BCG vaccination. a] Dot plot where individuals are represented by dots, and lines represents linear fit of responses b] Histograms of IFNc
response to M.tb PPD response in infants with hypovitaminosis (,30 ng/ml) and in infants with sufficient 25(OH)D.
doi:10.1371/journal.pone.0016709.g002
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D, suggesting that the increased vitamin D production is not just
local to the BCG inoculation. It is possible that the local increased
production of 1,25(OH)2D3 plays a role by influencing the
migration of the activated DCs from the site of vaccination to
the lymph nodes [36,37] resulting in further production of vitamin
D there.
Vitamin D association with IFNc response to M.tb PPD
Vitamin D has been shown to play an immuno-regulatory role
[20,23], and in particular has been shown to regulate IFNc
production [38,39]. It is possible that Vitamin D is produced as
part of the immuno-regulatory mechanism to control the pro-
inflammatory response produced following vaccination. Our
results show that 25(OH)D concentration is inversely associated
with the IFNc response to M.tb PPD following BCG vaccination 3
months post vaccination, but that this effect is weaker at 12
months. The weakening of the effect at 12 months could be due to
lower levels of Vitamin D being present at 12 compared to 3
months.
The paradoxical effects of vitamin D on Th1 mediated
immunity have been observed in tuberculosis whereby Vitamin
D treatment is associated with decreased Th1 mediated immunity,
but increased bactericidal activity [24]. Vitamin D supplementa-
tion of participants in a study resulted in increased killing of BCG
in vitro [40]. It would be interesting to further explore whether the
increased levels of Vitamin D observed in BCG vaccinated infants
are beneficial or harmful for the long term protection BCG offers
against tuberculosis and if the rate of tuberculosis is different
according to Vitamin D status, among vaccinees. Increased killing
of BCG may not be beneficial if BCG needs to remain alive within
the body to maintain protection against tuberculosis. On the other
hand, perhaps part of the mechanism of action of BCG against
tuberculosis is through increased production of Vitamin D
resulting in cathelicidin production and killing of M.tb. Given
that the Th1 response is protective, but also causes pathology,
Vitamin D may provide the ideal response: capable of inducing
increased bactericidal activity coupled with a decreased, but
present, Th1 response. Vitamin D status may thus have potential
as an additional biomarker of protection.
This study has the limitation that it was a small study and the
information on several known factors that influence Vitamin D
concentrations in infants, namely infants’ feeding practices,
vitamin supplementation in mothers or infants, and exposure to
sunlight, were not collected. However, it is unlikely that these
factors were associated with child vaccination status, as whether or
not infants received BCG vaccination depended solely on which
one of two neighbouring Primary Care Trusts they resided in. It is
thus unlikely that these known ‘‘risk factors’’ have confounded the
observed associations between BCG vaccination status and
Vitamin D concentrations. It is policy in both Primary Care
Trusts to follow Department of Health Guidelines on vitamin D
supplementation, and supplementation should therefore have been
similar in both settings during this study.
We believe that the findings of this observational study are both
interesting and important. Further studies, including a randomised
controlled trial, are now required to confirm that differences
between vaccinated and unvaccinated infants were not due to
differences in supplementation between the two sites. These
studies could be conducted in the UK where many infants are not
BCG vaccinated, in an area where BCG is not routinely offered
and in the absence of vitamin D supplementation, by randomising
infants to receive BCG vaccination or not. The findings of our
study, if confirmed in a randomised trial, would have important
implications for BCG vaccination and Vitamin D supplementation
policies.
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Table 5. Mean IFNc response to M.tb PPD by vitamin D status, controlling for season of blood collection at 3 and 12 months post
BCG, among vaccines.
No. of infants
Mean IFNc to
M.tb PPD (pg/ml)
Mean difference in IFNc
to M.tb PPD between
infants with low and high
vitamin D (95% CI) P value
3 months post
BCG
Hypovitaminosis
(,30 ng/ml)
20 2426 829 (84, 1575) * 0.030
Sufficient Vitamin D
(.30 ng/ml)
27 1597
Adjusted for season of
blood collection
883 (83, 1683) ** 0.031
12 months post
BCG
Vitamin D deficiency
(,20 ng/ml)
18 1542 466 (2352, 1283) * 0.255
Vitamin D (.20 ng/ml) 19 1076
Adjusted for season of
blood collection
523 (2375,1420) ** 0.244
*unadjusted (‘‘crude’’),
**adjusted.
doi:10.1371/journal.pone.0016709.t005
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